Sutent 50 mg hard capsules

DRUG3 trials

Sponsors

F. Hoffmann-La Roche AG, Bristol-Myers Squibb Services Unlimited Company, Region Hovedstaden

Conditions

Advanced MalignanciesMetastatic non-clear cell renal cell carcinomaPan tumor

Phase 2

Pan Tumor Study for Long-term Treatment of Cancer Patients Who Have Participated in BMS sponsored Trials Investigating Nivolumab and Other Cancer Therapies

RecruitingCTIS2023-506914-32-00

Bristol-Myers Squibb Services Unlimited CompanyPan tumor

Start: 2020-05-05Target: 307Updated: 2026-01-19

A phase II trial of an individualized treatment strategy for patients with metastatic non-clear cell renal carcinoma

Active, not recruitingCTIS2024-519070-39-00

Region HovedstadenMetastatic non-clear cell renal cell carcinoma

Start: 2020-03-06Target: 30Updated: 2024-10-31

Phase 3

An open label, multicenter extension study in patients previously enrolled in a Genentch and/or F. Hoffmann-La Roche Ltd sponsored atezolizumab study (IMBRELLA B)

Active, not recruitingCTIS2023-506184-34-00

F. Hoffmann-La Roche AGAdvanced Malignancies

Start: 2019-08-09Target: 104Updated: 2025-11-10